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Among the most frequent genomic alterations in malignant pleural 
mesothelioma (MPM) are the homozygous deletions (HD) of the CDKN2A tumor 
suppressor gene. These alterations are found in 49% of MPM patients according to a 
recent analysis of TCGA, The Cancer Genome Atlas 1. In our recent study published 
in the Journal of Thoracic Oncology performed on 78 short-term–cultured MPM cell 
lines, we found CDKN2A HD in 73% of patients 2. We also showed that the CDKN2A 
HD are accompanied in 30% of them by the HD of all genes encoding type I interferons 
(IFN I) that are essential for cellular antiviral defense. Finally, we identified two MPM 
cell lines with a constitutively activated IFN I response characterized by the expression 
of numerous IFN-stimulated genes (ISG) that resist to the oncolytic activity of the 
vaccine Schwarz strain of Measles virus (MV). 
Other frequent genomic alterations in MPM are the mutations and/or the HD of 
the BAP1 gene 1. In their letter to the editor, Yang H et al focus on The Cancer Genome 
Atlas (TCGA) data and show that BAP1 mutation and BAP1 HD are found in 22% and 
14% of patients respectively. They performed a functional enrichment analysis using 
Gene Ontology and Reactome databases to identify the signal pathways that correlate 
to BAP1 expression. They show a strong negative correlation between BAP1 
expression and a constitutively activated IFN I response. They conclude that BAP1 
loss-of-function may be used as a marker of tumors with constitutively activated IFN I 
response and thus resistance to oncolytic virotherapy.  
Hmeljak J et al previously performed an analysis of TCGA on 74 MPM patients 
with a detailed focus on BAP1 alteration and its consequences 1. They report an IFN I 
signature in MPM tumors with an inactivated BAP1 gene (Supplementary Figure 3H 
and Supplementary Figure 7D). Thus, the expression of BAP1, as well as its mutational 




































































Considering those results, we first analyzed BAP1 gene expression in 19 MPM 
cells lines for which we previously determined their MV-sensitivity 3. We observed a 
significant enrichment of low BAP1-expressing MPM cell lines that are MV-resistant 
(p=0.02) (Figure 1A). We then screened BAP1 gene alterations in these cell lines. 
Eight MPM cell lines harbor BAP1 alterations, 3 with HD and 5 with mutations (Figure 
1B). These data show that all MPM cell lines with IFNB1 deletion are sensitive to MV 
independently of the BAP1 mutation status. Interestingly, a slight enrichment of BAP1 
genetic alterations was observed in MV-resistant compared to MV-sensitive MPM cell 
lines (p=0.07), especially considering MPM cell lines without IFNB1 deletion (p=0.06) 
(Figure 1C).    
We thus analyzed the IFN I signature of 36 short-term–cultured MPM cell lines 
for which IFNB1 and BAP1 genetic alteration status have been determined (61% with 
BAP1, 28% with INFB1, 14% with both genes alteration). We performed a pathway 
enrichment analysis using transcriptomic data previously generated from these cell 
lines 4 and the online pathway analytic tool of Reactome Knowledgebase 
(https://reactome.org/). We did not find any significant enrichment of IFN I pathways 
on genes whose expression inversely correlates with BAP1 gene expression 
(Spearman´s r < -0.4, FDR-adjusted p < 0.01), neither on differentially expressed 
genes between MPM cell lines with or without BAP1 genetic alteration (data not 
shown). This absence of link between BAP1 expression or alteration and IFN I 
pathways was also observed in our previous study 2. In absence of virus, MV-resistant 
Meso61 cell line with a bi-allelic deletion and low expression of BAP1 harbors an 
inactivated IFN I response, while MV-resistant Meso45 with a high expression of wild-




































































Altogether, our results suggest a correlation between BAP1 gene expression or 
alteration status and the resistance to MV, but we cannot conclude on a link with the 
IFN I response. This discrepancy of the results between tumor samples and cell lines 
may be explained by the microenvironment. It was reported that BAP1-altered MPM 
tumors show a different pattern of infiltration by immune cells than wild-type BAP1 
tumors 5 and these infiltrations may play a role in the observed IFN I signature. 
Furthermore, this IFN I signature may be responsible for the presence of infiltrated 
immune cells as it was reported for other cancers 6. 
In conclusion, the negative correlation of BAP1 expression and the IFN I 
signature in MPM observed by Yang H et al could have a great interest in the context 
of absence of INFB1 deletion to identify patient with a lower chance to respond to 
oncolytic virotherapy using IFN I-sensitive oncolytic viruses. It would thus be interesting 
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Figure 1: Comparison of BAP1 gene expression and genetic alteration status to 
Measles virus sensitivity in malignant pleural mesothelioma cell lines. BAP1 
gene expression and mutation status were analyzed in 19 malignant pleural 
mesothelioma (MPM) cell lines characterized for Measles virus (MV) sensitivity in our 
previous study 3.  A. BAP1 gene expression was determined by RT-qPCR as 
previously described 7. MV resistant cell lines showed a significantly lower BAP1 
expression than MV sensitive cell lines (Mann Whitney test, p-value=0.02). B. BAP1 
mutation status was defined using a targeted next generation sequencing 8. Biallelic 
deletions were detected based on sequencing coverage. Sequencing data analysis 
showed mutations in 8 cell lines: (i) 3 cell lines with bi-allelic deletions of BAP1 exons, 
(ii) 2 with nonsense mutations, (iii) 2 with splice site mutations and (iv) 1 with missense 
mutation predicted to be functionally damaging by polyphen HDIV and SIFT.  C. MV 
sensitivity and INFB1 and BAP1 mutations profile in MPM cell lines were resumed in a 
heat map. BAP1 mutation and deletion are enriched in MV resistant cell lines compared 
to MV sensitive cell lines (Fisher’s exact test, p=0.07 in all MPM cell lines and p=0.06 
in MPM cell lines without INFB1 deletion). Statistical tests were performed using 
















































































meso 4 nonsense  chr3:52439233T>A K337* 
meso 47 splice site chr3:52443569C>T  
meso 52 splice site chr3:52443857C>A  
meso 61 deletion exon 6  
meso 76 missense  chr3:52441264T>G H169P 
meso 95 deletion all exons  
meso 150 deletion exons 14-17  













































































































MV sensitivity S S S S S S S S S S S S R R R R R R R
INFB1 DEL DEL DEL DEL DEL DEL DEL DEL WT WT WT WT WT WT WT WT WT WT WT
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INFB1  deletion status
WT : wild-type
DEL : Bi-allelic deletion
BAP1  mutation status
●  : wild-type
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